Dr. Stephen (Steven) Klein

speaker

467 appearances 1 recordings 1 series first heard Jul 2026 last heard 2 Jul

Dr. Stephen (Steven) Klein’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.

Appearances

newest first · ▶ plays the moment

RECOVERable: Mental Health and Addiction Experts Answer Your Questions · Ozempic and Cravings: How GLP-1 Drugs Work for Addiction · 2 Jul 2026 podcast

What difference can all this make?

Huge.

I think about the treatment center where I'm fortunate enough to work.

is really a place where I wish everyone had access to that.

I wish everyone had access to incredible therapy, wraparound clinical services, group therapy, spiritual therapy, things like that.

But it's not the way that our medical system is set up, and it's not reasonable to think that that's accessible to all people today.

Mm-hmm.

I think where these medications have incredible promises, one, if we can get over the accessibility barriers to these medications themselves, they could potentially be scalable addiction treatments that people could take on their own, mitigate their risk, decrease their risk of overuse, overdose, things like that.

But also, I think there's an incredible untapped

population, where we may be able to divert people from ever crossing the line into alcoholism or drug addiction.

So if someone is having a relationship with alcohol or opioids or nicotine that, again, takes away from their agency, they're not able to do things that align with their value system, could they start one of these medications earlier?

Is there a lower risk of overdose for people on GLP-1s?

What these big observational studies show is, yes, the British Medical Journal paper showed a decrease in 50% of all-cause substance use-related mortality, over 600,000 people taking them.

50%.

And almost 20% decrease in the individual measures.

So alcohol-related hospitalizations, alcohol-related relapse, almost 20% in all of those, but then jump to 50% for all-cause mortality related to substance use.

So I would say, yes, the idea is that patients are doing less of the substances that potentially can affect them negatively while on these medications.

Again, those are observational studies, so those are people who are on them for weight loss or type 2 diabetes.

We don't yet have the longitudinal study largely because it's not yet FDA approved to follow patients, say, who are leaving care and treatment centers on a GLP-1 long-term, what their relapse rates are.

Showing 241–260 of 467 · page 13 of 24